Kumar, B N Prashanth <br/><br/>
Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.  [electronic resource] 

 -  Molecular pharmaceutics  07 2018 
 - 2698-2713 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1543-8392 
<br/><br/><label>Standard No.: </label>10.1021/acs.molpharmaceut.8b00218  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Breast Neoplasms--drug therapy<br/>Catechin--analogs & derivatives<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Chemical Engineering<br/>Drug Carriers--chemistry<br/>Drug Resistance, Neoplasm--drug effects<br/>ErbB Receptors--metabolism<br/>Female<br/>Gold--chemistry<br/>Humans<br/>Metal Nanoparticles--chemistry<br/>Mice, Nude<br/>Piperidines--pharmacology<br/>Porosity<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Quinazolines--pharmacology<br/>Silicon Dioxide--chemistry<br/>Tamoxifen--pharmacology<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor Receptor-2--metabolism<br/>Xenograft Model Antitumor Assays